ATRS shares have a strong debt-to-equity ratio but their quick ratio which reads 1.80 is strong and might cause problems for them later in the future.
For the most recent quarter, the net income has jumped by +64.49%. This strength in their income has affected them and thus decreased their earnings to -$758,000. The sustained growth in their revenue has helped boost their earnings per share.
Analysts meanwhile rate Antares Pharma, Inc. (NASDAQ:ATRS) as a strong buy. Still some above discussed indicators of the $489.99M company show strength while others show weakness. There is little evidence at the moment to justify the expectation of the ATRS shares to either perform positively or negatively when compared to other stocks. The primary strengths of Antares Pharma, Inc. can be witnessed in its increased revenue, growing earnings per share, higher return on equity, increased operating cash and high net margin. Subsequently, financial analysis have also identified some weak areas that includes high debt, relatively high P/E ratio, lower return on assets and low net margin.